Radioiodination, purification, and evaluation of antihuman tumor‐derived immunoglobulin G light chain monoclonal antibody in tumor‐bearing nude mice. (13th March 2023)

• Record Type: Journal Article
• Authors: Sun, Hongwei; Yan, Ping; Wang, Rongfu; Du, Yujing; Zhang, Chunli; Guo, Fengqin; Kang, Lei; Cui, Yonggang
• Is Part Of: Journal of labelled compounds & radiopharmaceuticals. Volume 66:Number 3(2023)
• Page Start: 108
• Page End: 115
• Publication Date: 2023-03-13
• Subjects: antihuman tumor‐derived IgG light chain monoclonal antibody (4E9) -- radioiodination -- radionuclide imaging; Tracers (Chemistry) -- Periodicals; Radiopharmaceuticals -- Periodicals; 615.8424
• DOI: 10.1002/jlcr.4017
• Languages: English
• ISSNs: 0362-4803

Abstract

Abstract : We report the synthesis and biological evaluation of 131 I‐labeled antihuman tumor‐derived immunoglobulin G (IgG) light chain monoclonal antibody (4E9) ([ 131 I]I‐4E9) as a promising probe for tumor imaging. [ 131 I]I‐4E9 was synthesized in radiochemical yield of 89.9 ± 4.7% with radiochemical purity of more than 99%. [ 131 I]I‐4E9 showed high stability in normal saline and human serum. In cell uptake studies, [ 131 I]I‐4E9 exhibited favorable binding affinity and high specificity in HeLa MR cells. In biodistribution studies, [ 131 I]I‐4E9 showed high tumor uptake, high tumor/non‐tumor ratios, and specific binding in BALB/c nu/nu mice bearing human HeLa MR xenografts. Single‐photon emission computerized tomography (SPECT) imaging of [ 131 I]I‐4E9 in the HeLa MR xenograft model demonstrated clear visualization of tumor after 48 h and confirmed specific binding in tumor. These findings suggest that [ 131 I]I‐4E9 possesses favorable biological characteristics and warrants further investigation as a prospective probe for imaging and treatment of cancers. Abstract : We report the synthesis and biological evaluation of 131I‐labeled antihuman tumor‐derived immunoglobulin G (IgG) light chain monoclonal antibody (4E9) ([131I]I‐4E9) as a promising probe for tumor imaging.